The role of VDR gene BsmI (rs1544410) and FokI (rs10735810) polymorphisms in postmenopausal osteoporosis formation has been confirmed by the results of fairly large number of studies. However, pharmacogenetic aspects of above polymorphisms have not been adequately studied. The aim of this work is to study the serum levels of certain biochemical parameters, bone turnover markers, vitamin D and parathyroid hormone in women with postmenopausal osteoporosis in the dynamics of treatment by ibandronic acid, depending on VDR gene rs1544410 and rs10735810 polymorphisms. We examined 117 women in dynamics of postmenopausal osteoporosis treatment. The 12-month course therapy included ibandronic acid, calcium and cholecalciferol according to the standard regimen. Detection of genetic polymorphisms was carried out by polymerase chain reaction method in real time. Twice, before the therapy start and at the end of one, the basic biochemical parameters, as well as β-Crosslaps, osteocalcin, 25(OH) D and parathyroid hormone were studied in women blood serum. Women with postmenopausal osteoporosis in treatment dynamics are characterized by significant decrease in serum β-CrossLaps, osteocalcin and alkaline phosphatase (p<0.01), as well as an increase in 25(OH)D concentrations (p<0.01). Prior to the initiation of therapy, GG genotype of the rs10735810 polymorphism of the VDR gene was associated with lower osteocalcin concentrations than in AA genotype (p<0.01). Holders of GG genotype of VDR gene rs1544410 polymorphism, in comparison with other women, are characterized (p<0.01) by lower levels of alkaline phosphatase (before treatment) and calcium (before and after treatment), higher levels of parathyroid hormone (before and after treatment). The obtained results can be used to develop personalized antiresorptive therapy regimens in postmenopausal osteoporosis.
vitamin D receptor gene, polymorphisms, postmenopausal osteoporosis, treatment
1. Urano T., Inoue S. Genetics of osteoporosis. Biochem. Biophys. Res. Commun. 2014;452(2):287-93. doihttps://doi.org/10.1016/j.bbrc.2014.07.141.
2. Yang T. L., Shen H., Liu A., Dong S. S., Zhang L., Deng F. Y., Zhao Q., Deng H. W. A road map for understanding molecular and genetic determinants of osteoporosis. Nat Rev Endocrinol. 2020;16(2):91-103. doihttps://doi.org/10.1038/s41574-019-0282-7.
3. Povoroznyuk V. V., Reznichenko N. A., Maylyan E. A. Osnovnye ekstraskeletnye effekty vitamina D. Problemy osteologii. 2014;17(3):22-28.
4. Maylyan E. A., Reznichenko N. A., Maylyan D. E. Regulyaciya vitaminom D metabolizma kostnoy tkani. Medicinskiy vestnik Yuga Rossii. 2017;(1):12- 20. doihttps://doi.org/10.21886/2219-8075-2017-1
5. Abouzid M., Karazniewicz-Lada M., Glowka F. Genetic Determinants of Vitamin D-Related Disorders; Focus on Vitamin D Receptor. Curr Drug Metab. 2018;19(12):1042-1052. doi:https://doi.org/10.2174/1389200219666180723143552.
6. Banjabi A. A., Al-Ghafari A. B., Kumosani T. A., Kannan K., Fallatah S. M. Genetic influence of vitamin D receptor gene polymorphisms on osteoporosis risk. Int J Health Sci (Qassim). 2020;14(4):22-28.
7. Maylyan E. A. Vliyanie polimorfizma 283 A>G (BSMI) gena receptora vitamina D na razvitie osteoporoza u zhenschin v postmenopauze. Medicinskiy vestnik Yuga Rossii. 2016;4:32-38. doi:https://doi.org/10.21886/2219-8075-2016-4
8. Maylyan E. A. Associacii polimorfizma 283 A>G (BSMI) gena receptora vitamina D s osteoporozom u zhenschin v zavisimosti ot dlitel'nosti postmenopauzy. Nauchnye vedomosti Belgorodskogo gosudarstvennogo universiteta. Medicina. Farmaciya. 2017;38(12):12-21.
9. Rudenko E. V., Rudenko E. V., Samohovec O. Yu., Kobec E. V., Marozik P. M. Associaciya polimorfnyh variantov gena receptora vitamina D s pokazatelyami mineral'noy plotnosti kostnoy tkani u zhenschin v menopauze. Izvestiya Nacional'noy akademii nauk Belarusi. Seriya medicinskih nauk. 2019;16(2):192-201. doi:https://doi.org/10.29235/1814-6023-2019-16- 2-192-201
10. Zhang L., Yin X., Wang J., Xu D., Wang Y., Yang J., Tao Y., Zhang S., Feng X., Yan C. Associations between VDR Gene Polymorphisms and Osteoporosis Risk and Bone Mineral Density in Postmenopausal Women: A systematic review and Meta-Analysis. Sci Rep. 2018;8(1):981. doi: https://doi.org/10.1038/s41598-017-18670-7.
11. Fu L., Ma J., Yan S., Si Q. A meta-analysis of VDR polymorphisms and postmenopausal osteoporosis. Endocr Connect. 2020:EC-20-0296.R1. doi: 10.1530/ EC-20-0296.
12. Creatsa M., Pliatsika P., Kaparos G., Antoniou A., Armeni E., Tsakonas E., Panoulis C., Alexandrou A., Dimitraki E., Christodoulakos G., Lambrinoudaki I. The effect of vitamin D receptor BsmI genotype on the response to osteoporosis treatment in postmenopausal women: a pilot study. J Obstet Gynaecol Res. 2011;37(10):1415-22. doi: https://doi.org/10.1111/j.1447- 0756.2011.01557.x.
13. Conti V., Russomanno G., Corbi G., Toro G., Simeon V., Filippelli W., Ferrara N, Grimaldi M., D’Argenio V., Maffulli N., Filippelli A. A polymorphism at the translation start site of the vitamin D receptor gene is associated with the response to anti-osteoporotic therapy in postmenopausal women from southern Italy. Int J Mol Sci. 2015;16(3):5452-66. doi: 10.3390/ ijms16035452.
14. Masheyko I. V. Biohimicheskie markery v ocenke processov remodelirovaniya kostnoy tkani pri osteopenii i osteoporoze. Zhurnal Grodnenskogo gosudarstvennogo medicinskogo universiteta. 2017;(2):149-153.
15. Park S. Y., Ahn S. H., Yoo J. I., Chung Y. J., Jeon Y. K., Yoon B. H., Kim H. Y., Lee S. H., Lee J., Hong S. Position Statement on the Use of Bone Turnover Markers for Osteoporosis Treatment. J Bone Metab. 2019; 26(4):213-224. doi:https://doi.org/10.11005/jbm.2019.26.4.213.
16. Fontalis A., Eastell R. The challenge of long-term adherence: The role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone. 2020;136:115336. doi:10. 1016/j. bone. 2020.115336
17. Li W. F., Hou S. X., Yu B., Li M. M., Fyrec C., Chen J. M. Genetics of osteoporosis: accelerating pace in gene identification and validation. Hum Genet. 2010;127(3):249-85. doi:https://doi.org/10.1007/s00439-009-0773-z.
